OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
27 mars 2024 13h00 HE
|
OSE Immunotherapeutics
Financial highlights €18.7 million available cash as of December 31st, 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February...
OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer
13 juil. 2022 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, July 13, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer,...
OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting
23 juin 2022 12h52 HE
|
OSE Immunotherapeutics
NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General...
OSE Immunotherapeutics Announces Collaboration with Microsoft
16 juin 2022 01h30 HE
|
OSE Immunotherapeutics
OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech event.This collaboration will give OSE the opportunity to further...
OSE Immunotherapeutics Appoints its International Scientific Advisory Board
09 juin 2022 12h00 HE
|
OSE Immunotherapeutics
The Scientific Advisory Board (SAB) combines the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy.The...
Four Poster Presentations at 2022 ASCO Annual Meeting
07 juin 2022 01h30 HE
|
OSE Immunotherapeutics
NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient-Reported Outcomes Versus ChemotherapyPositive Interim Results in Phase 2...
OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi® in Immuno-Oncology at ASCO 2022
23 mai 2022 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, May 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione...
OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
18 mai 2022 12h00 HE
|
OSE Immunotherapeutics
A Phase 1 Study Sponsored and Conducted by Veloxis Pharmaceuticals, Inc., the Company’s Partner in Transplantation NANTES, France, May 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:...
OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston
11 mai 2022 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, May 11, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at two...
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology
03 mai 2022 12h00 HE
|
OSE Immunotherapeutics
Initiation of the Phase 1 clinical expansion trial triggers a €10 million milestone payment from Boehringer Ingelheim to OSE Immunotherapeutics.The trial is being conducted in advanced hepatocellular...